For Industry

For drug developers who need to rapidly screen therapeutic agents against broad cancer populations, First Ascent Biomedical has developed a first-in-kind AI/ML platform and cell growth technology that accelerates the drug development pipeline.

Our Drug Prediction Platform provides real-time pharmacological and multi-omics pre-clinical data that support: drug development, repurposing and repositioning; expanding access and indications for use; mechanism-driven drug combination design; explainable multi-omics biomarker development; as well as trial pre-enrollment patient screening and companion diagnostics development.

To date, we have completed therapeutic development projects with eight biotech and pharmaceutical partners. Additionally, we have a growing biobank of patient-derived samples, and pharmacogenomic biomarker AI/ML for preclinical and clinical datasets of all sizes.

Our Drug Prediction Platform provides real-time pharmacological and multi-omics pre-clinical data that support: drug development, repurposing and repositioning; expanding access and indications for use; mechanism-driven drug combination design; explainable multi-omics biomarker development; as well as trial pre-enrollment patient screening and companion diagnostics development.

To date, we have completed therapeutic development projects with eight biotech and pharmaceutical partners. Additionally, we have a growing biobank of patient-derived samples, and pharmacogenomic biomarker AI/ML for preclinical and clinical datasets of all sizes.

Our Drug Prediction Platform provides real-time pharmacological and multi-omics pre-clinical data that support: drug development, repurposing and repositioning; expanding access and indications for use; mechanism-driven drug combination design; explainable multi-omics biomarker development; as well as trial pre-enrollment patient screening and companion diagnostics development.

To date, we have completed therapeutic development projects with eight biotech and pharmaceutical partners. Additionally, we have a growing biobank of patient-derived samples, and pharmacogenomic biomarker AI/ML for preclinical and clinical datasets of all sizes.

Pharmaceutical Industry

First Ascent Biomedical Drug Prediction Platform – DxPP

Real-time Preclinical Drug Development (Pre-Clinical Trial)

DxPP Pre-Clinical Development Trial Pre-Screen

Response-Driven Precise Patient Selection

Explainable AI/ML Multi-Omics Biomarkers

Our DxPP Accelerates the Oncology Drug Pipeline at Every Phase

Real-time Preclinical Drug Development (Pre-Clinical Trial)

First-in-kind product and technology enables single drug and drug combination testing direct from patient tumor tissue samples without compromising patient care.
Pharmacological and multi-omics data represents clinically relevant and biologically diverse patient cohorts.
Pharmacological testing against therapy resistant cell and tumor bulk populations better measure therapeutic impact in complex, heterogenous tumors.

Response-Driven Precise Patient Selection

Empowers precise pre-enrollment screening for oncology clinical trials to identify patients more likely to respond to the trial therapy
Enables fine-tuned clinical trial populations
Deployed as a companion diagnostic for clinical use of approved therapeutics

Explainable AI/ML Multi-Omics Biomarkers

Has been published on and validated repeatedly across multiple cancer types.
Integrates complex pharmacological and multi-omics datasets to identify easy to understand and implement pharmacogenomic biomarkers.
Can identify biomarkers using data from First Ascent’s Drug Production Platform or through pre-clinical or clinical datasets developed from other sources for multiple pre-clinical or clinical endpoints, including efficacy and safety.
Our Drug Prediction Platform integrates our drug testing and genomics data through our xAI/ML to enable concurrent pan-cancer pre-clinical drug development and pan-cancer biomarker development programs.
xAI/ML biomarkers identify mechanism-driven drug combination partners for monotherapy assets requiring improved efficacy.
xAI/ML biomarkers support programs for expanding access and expanding indications for approved therapeutics.